Mupadolimab (CPI-006)
Non-Small Cell Lung Cancer (NSCLC)
Key Facts
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is focused on developing precisely-targeted medicines for difficult-to-treat cancers and immune diseases, with a core platform centered on ITK inhibition. Founded in 2014, the company has advanced its lead candidate, soquelitinib, through Phase 1 trials and maintains a broader clinical pipeline including ciforadenant and mupadolimab. Led by industry veterans who previously developed Rituxan and Imbruvica, Corvus leverages a biomarker-driven, clinical science approach to increase development success and is publicly traded on NASDAQ.
View full company profileAbout Corvus Pharmaceuticals
Corvus Pharmaceuticals is focused on developing precisely-targeted medicines for difficult-to-treat cancers and immune diseases, with a core platform centered on ITK inhibition. Founded in 2014, the company has advanced its lead candidate, soquelitinib, through Phase 1 trials and maintains a broader clinical pipeline including ciforadenant and mupadolimab. Led by industry veterans who previously developed Rituxan and Imbruvica, Corvus leverages a biomarker-driven, clinical science approach to increase development success and is publicly traded on NASDAQ.
View full company profileTherapeutic Areas
Other Non-Small Cell Lung Cancer (NSCLC) Drugs
| Drug | Company | Phase |
|---|---|---|
| NBTXR3 + anti-PD1 | Nanobiotix | Phase 1 |
| TTFields | Novocure | Phase 3 |
| VAC2 | Lineage Cell Therapeutics | Phase 1 |
| TG6050 | Transgene SA | Preclinical |
| Monalizumab (IPH2201) | Innate Pharma | Phase 3 |
| Plinabulin | BeyondSpring | Phase 2/3 |
| PD1-Vaxx (IMU-201) | Imugene | Phase 1 |
| ATNM-400 | Actinium Pharmaceuticals | Preclinical |
| Reqorsa® (quaratusugene ozeplasmid) + Keytruda® (pembrolizumab) | Genprex | Phase 1/2 |
| ABD-3001 | Advanced Biodesign | Phase 1 |